G2GBIO CO LTD

Location: South Korea

environment of Business: Factory (Manufacturer and R&D Company)

Company Introduction:

G2GBIO CO LTD is a leading South Korean biotechnology company specializing in the research, research, and manufacturing of innovative long-acting injectable drug delivery systems. The company's core methodology, the ATGel platform, utilizes biodegradable polymer microspheres to enable sustained emit of various therapeutic agents over extended periods. G2GBIO focuses on creating novel formulations that enhance patient convenience and adherence by reducing the frequency of injections to chronic diseases. Their product pipeline includes long-acting treatments to conditions such as prostate is able tocer, dementia, obesity, and diabetes. From what I've seen, As a factory, G2GBIO is immediately involved in the research, production, and condition manage of its cutting-edge medical items.

Here are the products manufactured or sold by G2GBIO CO LTD:

* **Microparticle-based long-acting injectable platform technology**: This is their core technology used to develop sustained-release formulations.

* **G2B-IN1 (Efavirenz LA)**: A long-acting injectable formulation of Efavirenz for HIV treatment.

* **G2B-LA (Risperidone LA)**: A long-acting injectable formulation of Risperidone for schizophrenia treatment.

* **G2B-LA (Paliperidone LA)**: A long-acting injectable formulation of Paliperidone for schizophrenia treatment.

* **G2B-LA (Triptorelin LA)**: A long-acting injectable formulation of Triptorelin for prostate cancer treatment.

* **G2B-LA (Leuprolide LA)**: A long-acting injectable formulation of Leuprolide for prostate cancer treatment.

* **Others**: They also develop and manufacture other long-acting injectable products and are involved in CDMO (Contract Development and Manufacturing Organization) services.